Sugi Predict

Sugi Predict / Compounds / SCHEMBL10054233

SCHEMBL10054233

SCHEMBL10054233

COc1ccc(/C=C/C(=O)C(C)(C)C(=O)/C=C/c2ccc(OC)c(OC)c2)cc1OC

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.82
▸ KDM4E B2RXH2 2/20 0.69
▸ ALDH1A1 P00352 2/20 0.69
▸ SMN1; SMN2 Q16637 2/20 0.69
▸ HPGD P15428 1/20 0.69
▸ ALOX15 P16050 1/20 0.69
▸ MAPK1 P28482 1/20 0.69
▸ HSD17B10 Q99714 1/20 0.69
▸ NFE2L2 Q16236 1/20 0.67
▸ ABCG2 Q9UNQ0 4/20 0.65
▸ MEN1 O00255 2/20 0.65
▸ TNFRSF1A P19438 1/20 0.58
▸ JUN P05412 1/20 0.57
▸ NFKB1 P19838 1/20 0.57
▸ PDE4A P27815 1/20 0.57
▸ PDE4B Q07343 1/20 0.57
▸ PDE4C Q08493 1/20 0.57
▸ PDE4D Q08499 1/20 0.57
▸ CA1 P00915 1/20 0.57
▸ CA2 P00918 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30130359 1.00 KMT2A (0.82) KMT2AKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL29497174 1.00 KMT2A (0.82) KMT2AKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL30130358 1.00 KMT2A (0.82) KMT2AKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL23903017 0.93 KMT2A (0.72) KMT2AKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL28794454 0.93 KMT2A (0.72) KMT2AKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL15000363 0.92 KMT2A (0.70) KMT2AKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL20117351 0.91 KMT2A (0.69) KMT2AKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL3125894 0.90 KMT2A (1.00) KMT2AKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL3125899 0.90 KMT2A (1.00) KMT2AKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL8965766 0.88 CYP2D6 (0.72) KMT2AKDM4EALDH1A1HPGDALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110312502-B Personal care compositions 联合利华知识产权控股有限公司 2022-06-24 — — CN claimed
EP-3582747-B1 A PERSONAL CARE COMPOSITION UNILEVER GLOBAL IP LTD (GB) 2021-10-13 — — EP claimed
EP-4351739-A2 COMPOSITIONS AND METHODS FOR CONTROLLING SWEAT PRODUCTION Unilever IP Holdings B.V. (NL) 2024-04-17 — — EP disclosed
WO-2022258385-A2 COMPOSITIONS AND METHODS FOR CONTROLLING SWEAT PRODUCTION UNILEVER IP HOLDINGS B.V. (NL) 2022-12-15 — — WO disclosed
CN-110312502-B Personal care compositions 联合利华知识产权控股有限公司 2022-06-24 — — CN disclosed
CN-110312502-B Personal care compositions 联合利华知识产权控股有限公司 2022-06-24 — — CN disclosed
EP-3582747-B1 A PERSONAL CARE COMPOSITION UNILEVER GLOBAL IP LTD (GB) 2021-10-13 — — EP disclosed
EP-3150203-A1 COMPOUNDS WITH (1E,6E)-1,7-BIS-(3,4- DIMETHOXYPHENYL)-4,4-DISSTITUTED-HEPA-1,6-DIENE-3,5-DI-ONE STRUCTURAL SCAFFOLD,THEIR BIOLOGICAL ACTIVITY, AND USES THEREOF Allianz Pharmascience Ltd (TW) 2017-04-05 — — EP disclosed
US-9562025-B2 Compounds with (1E, 6E)-1,7-Bis-(3,4-dimethoxyphenyl)-4-4-distributed-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof ALLIANZ PHARMASCIENCE LTD. (TW) 2017-02-07 — — US disclosed
US-20160264539-A1 COMPOUNDS WITH (1E, 6E)-1,7-BIS-(3,4-DIMETHOXYPHENYL)-4-4-DISUBSTITUTED-HEPTA-1,6-DIENE-3,5-DIONE STRUCTURAL SCAFFOLD, THEIR BIOLOGICAL ACTIVITY, AND USES THEREOF Annji Pharmaceutical Co., Ltd. (TW) 2016-09-15 — — US disclosed
US-20150190351-A1 Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof Annji Pharmaceutical Co., Ltd. (TW) 2015-07-09 — — US disclosed
US-9000222-B2 Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof ANDROSCIENCE CORPORATION (US) 2015-04-07 — — US disclosed
US-20130143969-A1 CURCUMIN COMPOSITIONS AND USES THEREOF THE OHIO STATE UNIVERSITY (US) 2013-06-06 — — US disclosed
US-20120053208-A1 Curcumin Analogs as Dual JAK2/STAT3 Inhibitors and Methods of Making and Using the Same THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2012-03-01 — — US disclosed
WO-2012024405-A2 CURCUMIN COMPOSITIONS AND USES THEREOF THE OHIO STATE UNIVERSITY (US) 2012-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130143969-A1 CURCUMIN COMPOSITIONS AND USES THEREOF DNMT1, DNMT3B, UGT1A7 KMT2A 698/4885KDM4E 594/4885ALDH1A1 225/4885
US-20120053208-A1 Curcumin Analogs as Dual JAK2/STAT3 Inhibitors and Methods of Making and Using the Same JAK2, STAT3, STAT5B KMT2A 830/4885KDM4E 1386/4885ALDH1A1 2166/4885
US-20150190351-A1 Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof AR, BRCA1, CYP17A1 KMT2A 2312/4885KDM4E 1922/4885ALDH1A1 62/4885
US-20160264539-A1 COMPOUNDS WITH (1E, 6E)-1,7-BIS-(3,4-DIMETHOXYPHENYL)-4-4-DISUBSTITUTED-HEPTA-1,6-DIENE-3,5-DIONE STRUCTURAL SCAFFOLD, THEIR BIOLOGICAL ACTIVITY, AND USES THEREOF AR, CYP17A1, SRD5A1 KMT2A 2381/4885KDM4E 848/4885ALDH1A1 181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.